ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byDarren SIGAL, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Abivax S.A.

No Placebo Group

Trial Summary

What is the purpose of this trial?

Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma

Research Team

Darren SIGAL, MD

Principal Investigator

Scripps Clinic/Scripps MD Anderson Cancer Center

Eligibility Criteria

Inclusion Criteria

Patients with ECOG performance status 0 or 1

Patients with histologically confirmed diagnosis of HCC not amenable to curative surgery or local therapy

You have received treatment for liver cancer before.

See 10 more

Exclusion Criteria

Patients with diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days before first study dose

Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose

Patients with minor surgery to liver or another site within 1 week before first study dose

See 5 more